
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx Inc demonstrated significant revenue growth in Q2, with total revenue increasing to $422K from $197K in the previous quarter, indicating a positive momentum for the company. Projections suggest continued strong revenue growth, with expectations of reaching $1.3 million in 2025 and escalating further to $4.5 million in 2026, reflecting the potential market demand for its innovative therapeutic offerings. As a clinical-stage biopharmaceutical company, RenovoRx is positioned to capitalize on its proprietary Trans-Arterial Micro-Perfusion therapy platform, which targets high unmet medical needs in cancer treatment, thus suggesting a robust outlook for future financial performance.
Bears say
RenovoRx Inc. reported revenue of $0.4 million and a net loss of $2.9 million, resulting in an earnings per share (EPS) of $(0.08), which aligns with consensus estimates but highlights ongoing financial challenges. The company operates in the context of pancreatic cancer, which has an alarmingly low 5-year survival rate of only 12%, underscoring the substantial risk associated with its target market. While some growth prospects exist, the significant uncertainties in clinical advancement and financial stability contribute to a negative outlook on RenovoRx's stock.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares